What we're reading, April 15, 2016: troubling disparities in access to preventive care remain; new test to choose the right hepatitis C medication could save money; and upcoming loss of exclusivity for some drugs could mean big savings for the healthcare system.
There are troubling disparities in access to recommended preventive care, according to a new report. Not only is having a dedicated healthcare provider key to getting preventive care, but so is income and geography, reported STAT. Addressing these disparities means improving access through house calls, urgent care centers, and mobile medical clinics. The study found that half of adults between the ages of 50 and 74 with incomes less than $25,000 had a colorectal screening compared with three-quarters of people of the same age making $75,000 or more.
New tests to help choose the right hepatitis C virus medication could save money. The Washington Post reported that Quest Diagnostics’ newest tests can predict whether or not Zepatier and Daklinza will successfully fight a patient’s specific type of hepatitis C. With 6 virus genotypes, plus some subtypes, choosing the right drug can mean curing a patient and preventing the waste of money for the wrong treatment. The tests cost no more than $750.
The impact of loss of exclusivity of drugs can have on lowering healthcare costs should not be overlooked. According to Forbes, while total spending on prescription drugs rose 12.2% in 2015, some of the drugs that Americans spend the most money on are about to become a lot cheaper through increased competition. Biosimilars are being created for the drugs that Americans spend the second and third most money on: Enbrel and Humira, both for rheumatoid arthritis. In addition, the fourth drug on the list is Crestor, for lowering cholesterol, which is about to lose patent protection, potentially driving costs down by as much as 90%.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More